Skip to content

The effect of Baduanjin exercise on cardiac rehabilitation in patients with stable coronary artery disease: a randomized controlled trial

Study on the establishment and clinical assessment of integrated treatment of traditional Chinese and western medicine for stable coronary artery disease

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IOR-17014149
Enrollment
Unknown
Registered
2017-12-26
Start date
2017-12-13
Completion date
Unknown
Last updated
2018-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

stable coronary artery disease

Interventions

Control group:Conventional treatment of integrated traditional Chinese and western medicine which referred to the unit therapy of integrated traditional Chinese and Western Medicine with coronary hear
Intervention group:Conventional treatment of integrated traditional Chinese and western medicine plus Baduanjin exercise which referred to gymnastic qigong-Baduanjin draw up by the Health Qigong manag

Sponsors

First Teaching Hospital of Tianjin University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
35 Years to 79 Years

Inclusion criteria

Inclusion criteria: 1. Aged 35 to 79 years; 2. Compliance with diagnostic criteria of stable coronary heart disease; 3. Classification of CCS cardiac function beween I-III; 4. Submitted informed consent.

Exclusion criteria

Exclusion criteria: 1. Left main coronary artery stenosis; 2. Uncontrolled hypertension or systolic pressure=160mmHg and/or diastolic pressure=100mmHg after taken medicine; 3. Uncontrolled rapid arrhythmias with symptoms or hemodynamic disorders; 4. High or complete atrioventricular block; 5. acute endocarditis; 6. Obstructive hypertrophic cardiomyopathy; 7. Symptomatic severe aortic stenosis, decompensated heart failure, acute pulmonary embolism, deep vein thrombosis, acute pericarditis, myocarditis and acute aortic dissection; 8. Chronic pulmonary disease with dyspnea; 9. Stroke or transient ischemic attack with cognitive impairment in the short term; 10. The clinical problems that have not been corrected, such as infection, severe anemia, electrolyte disorder, hyperthyroidism, etc; 11. The abnormal function of liver and kidney (serum alanine aminotransferase or creatinine > 2 times the upper limit of normal reference value); 12. Unable to exercise due to limb disorders or other reasons; 13. Patients who are included in other clinical trials in the recent 1 months; 14. Other situations that researchers considered not suitable for the trial.

Design outcomes

Primary

MeasureTime frame
Cardiopulmonary exercise test: oxygen uptake (VO2), metabolic equivalent, O2 Pulse, Exercise load (watt), Exercise time, Hate rate, etc;Syndrome scoring table of Traditional Chinese Medicine;Four items of blood lipid (TC, TG, LDL-C, HDL-C);

Secondary

MeasureTime frame
The integral of angina pectoris;Five-level Euro Qol five-dimen sional questionnaire (EQ-5D-5L);General Hospital Anxiety and Depression scale (HAD);High sensitive C-reactive protein (hs-crp);Composite end point (all causes of death, acute coronary syndrome, blood revascularization, heart failure, malignant arrhythmia, cardiogenic shock, stroke, pulmonary embolism, etc);

Countries

China

Contacts

Public ContactWang Xianliang

First Teaching Hospital of Tianjin University of Traditional Chinese Medicine

xlwang1981@126.com+86 13920007825

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026